Market Intelligence, Clinical Progress, and High-Purity Reagents for Stress-Related Disorders, Endocrine Development, and Metabolic Indications.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CRHR1 (Corticotropin-Releasing Hormone Receptor 1) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Cell-Based Assay Platform | CRHR1 Lentivirus Premade Particles Optimized for stable cell line generation. HEK293 expressed for native folding and 7-transmembrane conformation. |
View CRHR1 Products |
| Antigen / ECD Protein | CRHR1 ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View CRHR1 Products |
| Gene Delivery | CRHR1 Promise-ORF / Plasmid Full-length ORF for transfection and custom cell lines. Sequence Verified. |
View CRHR1 Products |
| Benchmark Control | Anti-CRHR1 Reference Antibody & Ligand Peptide Recombinant positive control for binding assays, FACS, and immunoprecipitation. High Purity (>95%). |
View CRHR1 Products |
| Validator | CRHR1 siRNA Set For knockdown verification and specificity controls (validated >80% knockdown). |
View CRHR1 Products |
| Related Target A | CRHR2 Subfamily selectivity screening (70% homology). Crucial for CNS/peripheral discrimination and avoiding cardiac off-target effects. |
View CRHR2 Products |
| Related Target B | POMC (ACTH Precursor) Downstream pathway activation marker for HPA axis modulation. |
View POMC Products |
| Related Target C | CRH (Corticotropin Releasing Hormone) Native ligand for binding competition assays and pathway activation studies. |
View CRH Products |
| Related Target D | AVPR1B (Vasopressin Receptor 1B) HPA axis synergy partner; stress response pathway comparator. |
View AVPR1B Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformation Maintenance (Class B) | Lentivirus-based stable cell lines preserve 7TM structure and native glycosylation for accurate cAMP, calcium flux, and internalization assays. |
| CRHR2 Subfamily Counter-Screening | Matched sets of CRHR1 and CRHR2 lentiviral reagents for robust selectivity profiling; homolog panel ECD proteins verified by mass spec. |
| Lack of Positive Controls | High-purity reference peptides, sequence-verified antibodies, and validated siRNA included for assay standardization. |
| Target Validation / False Positives | Validated siRNA sets for knockdown verification; mutant CRHR1 constructs available for resistance testing. |
| Cross-species Evaluation | Human/Mouse/Cyno ortholog proteins available with >95% purity; sequence identity >98% for CNS penetration and behavioral model studies. |
Live CRHR1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The CRHR1 therapeutic landscape has undergone significant recalibration. First-generation small molecule antagonists (pexacerfont, verucerfont) failed in Phase III for depression and anxiety due to lack of efficacy and hepatotoxicity signals. Current R&D has pivoted toward more precisely targeted indications. Neurocrine Biosciences' Crinecerfont achieved breakthrough success in Congenital Adrenal Hyperplasia (CAH), reducing androgen excess with profound clinical benefit. Spruce Biosciences is advancing similar antagonists. Beyond CAH, the field is exploring next-generation approaches: biased signaling (G-protein vs. β-arrestin selective ligands) to reduce desensitization, allosteric modulation for pathway-specific control, and peripherally-restricted antagonists for metabolic and inflammatory indications. Emerging targets include Cushing's disease (pituitary-directed), stress-induced relapse in addiction, irritable bowel syndrome, and metabolic syndrome. The demand for sophisticated assays—especially those discerning CRHR1/CRHR2 selectivity, signaling bias, and CNS penetration—has intensified.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Antagonist | Neurocrine Biosciences, Spruce Biosciences, Astellas Pharma | Congenital Adrenal Hyperplasia (CAH), Cushing's Disease, Depression | Functional GPCR assay (Lentivirus for cell lines); CRHR2 selectivity assay; cAMP/calcium flux readouts |
| Biased Ligand (G-protein selective) | Academic Consortia, Structure-based design groups | Anxiety, PTSD | Internalization assay (β-arrestin recruitment monitoring); stable cell line for pathway-specific readouts |
| Allosteric Modulator | Emerging biotech | Metabolic Syndrome | Orthosteric/Allosteric binding competition; high-purity ECD domains for SPR/Tm shift |
| Peptide Analogs | Academic / Biotech | Stress-related GI disorders | Binding/internalization assay; precise cell models for receptor trafficking |
| Peripheral Antagonist | Clinical stage pivots | Irritable Bowel Syndrome | BBB permeability surrogates; peripheral vs CNS receptor binding with free ECD capture |
| Monoclonal Antibodies | Emerging Biotech | Neuroinflammation | Epitope mapping (N-terminal ECD / mutants); FACS and immunohistochemistry |